Bronconex Acticap

국가: 뉴질랜드

언어: 영어

출처: Medsafe (Medicines Safety Authority)

유효 성분:

Mometasone furoate 400ug (anhydrous)

제공처:

Organon (New Zealand) Limited

INN (International Name):

Mometasone furoate 400 µg (anhydrous)

복용량:

400 mcg/dose

약제 형태:

Powder for inhalation

구성:

Active: Mometasone furoate 400ug (anhydrous) Excipient: Lactose

패키지 단위:

Inhaler, metered, DPI, (sample), 14 dose units

수업:

Prescription

처방전 유형:

Prescription

Manufactured by:

MSD International GmbH (Singapore Branch)

치료 징후:

Bronconex Acticap is indicated for prophylactic therapy in the management of patients with asthma of all severities, including patients who have been dependent upon either inhaled or systemically administered corticosteroids and non-corticosteroid-dependent patients inadequately controlled on other drug regimens.

제품 요약:

Package - Contents - Shelf Life: Inhaler, metered, DPI, (sample) - 14 dose units - 18 months from date of manufacture stored at or below 25°C - Inhaler, metered, DPI - 30 dose units - 18 months from date of manufacture stored at or below 25°C - Inhaler, metered, DPI - 60 dose units - 18 months from date of manufacture stored at or below 25°C

승인 날짜:

2000-12-05